Biocon Biologics receives FDA approval for biosimilar YESINTEK
Express Pharma
DECEMBER 1, 2024
Biocon Biologics, a global biosimilars company and subsidiary of Biocon, has announced that the U.S. Food and Drug Administration (FDA) has approved YESINTEK (Ustekinumab-kfce). The biosimilar is a monoclonal antibody designed to treat Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The company had previously informed the Stock Exchange on 29 February 2024 about its settlement and licensing agreement with Janssen Biotech, Janssen Sciences Ireland, and Johnson &
Let's personalize your content